A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Phase 3 Active, not recruiting NCT04175600

Summary

The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.

Double-blind Period: Time to Disease Progression

Placebo arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 199 weeks); Selexipag arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 213 weeks) · Months

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
• Improving Hypertension Medication Adherence for Older Adults — University of Arizona
• LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
• SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca
• Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test — Stanford University

All trials